Presentation is loading. Please wait.

Presentation is loading. Please wait.

EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance.

Similar presentations


Presentation on theme: "EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance."— Presentation transcript:

1 EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance

2 EPAA Conference 2006 Workshop Regulatory Acceptance, June 2007 Highlighted the importance of acceptance at a global level Addressed a plea to the EU to maintain alternative approaches on the agenda of the regulatory dialogue with trading partners

3 Action currently being undertaken Mainly in a multilateral context On the basis of procedures that, according to sectors, are more or less formally established Progress being verified in regulatory dialogue on a bilateral level

4 Chemicals Main forum for discussion is the OECD Principle of Mutual Acceptance OECD guidance N° 34 OECD Test Guidelines, adopted as testing methods in EU regulation for chemicals

5 Pharmaceuticals At the request of the Commission, the EMEA has conducted a review of current international (ICH) non- clinical guidelines to see whether they were up to date and whether their was scope to promote the 3Rs agenda. Based on the Safety Working Parties scientific review, the European Commission then proposed a review of the ICH guidelines by ICH A formal review started at the June 2006 ICH meeting

6 ICH Steering Committee May Confirmed its commitment to the 3Rs agenda, with a view to the replace, reduce or refine animal testing when drafting new or revising existing guidelines. Is committed to ensuring that groups working on ongoing and new topics document their impact on animal testing

7 From the EU initiated ICH review, three ICH guidelines are under revision carcinogenicity, genotoxicity and the non-clinical studies necessary for human trials guidelines. The European Commission is confident that the ongoing ICH work will have a positive impact for the three-Rs agenda

8 Cooperation with validation bodies First contacts took place between the non-clinical safety experts working within ICH and the organisations for Validation of Alternative Methods in the three regions Update on ongoing activities regarding alternative methods to animal testing and looking for ways to increase mutual understanding and collaboration

9 European Directorate for the Quality of Medicines & HealthCare, EDQM Council of Europe European Pharmacopeia In accordance with the European Convention …… the Ph. Eur. Commission (Council of Europe) is committed to the reduction of animal usage, wherever possible, in pharmacopoeia testing and encourages those associated with its work to seek alternative procedures. An alternative or modified method is adopted by the Commission once it has been clearly demonstrated that it offers satisfactory control for pharmacopoeial purposes

10 European Directorate for the Quality of Medicines & HealthCare, EDQM Council of Europe Progress has been made in implementing the 3Rs EDQM has initiated an enquiry aimed at verifying to what extent 3R methods have been transposed and are being implemented by stakeholders Collaboration has been established between EDQM and ECVAM.

11 Cosmetics First meeting European Commission, FDA, Health Canada and the Ministry of Health, Labour and Welfare, Japan, in September, 2007 in Brussels to discuss regulatory issues relating to cosmetic products. Establishment of the ICCR, the "International Cooperation on Cosmetic Regulation", for information exchange aiming at ensuring safety of cosmetic products through international cooperation

12 Alternative methods identified as a priority Intensive collaboration and communication in the design, execution, and peer review of validation studies should be further strengthened ICCVAM, ECVAM, JaCVAM and Canada should address this issue and propose options to ensure a collaborative approach They should be supported by scientific experts from the regulatory bodies

13 Regulatory authorities committed to implementation of 3R approaches Need to involve regulators in validation processes Experience suggests that if there are substantial discrepancies between U.S. and EU at the regulation stage, they are usually due to different appraisals at the peer review stage Cooperation, also on peer review, might be strengthened by an International Council of Validation Bodies Overall assessment


Download ppt "EPAA Conference 5 November 2007 Georgette LALIS Enterprise and Industry DG European Commission The international dimension of regulatory acceptance."

Similar presentations


Ads by Google